Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Haroche

Showing results (1-10 of 284) with videos related to

Pageof 29
Sort By:
Pediatric Blood & Cancer|January 10, 2017
Targeting BRAK, MEK, mTOR, and now AKT in histiocytosis: The ongoing revolution of therapies in orphan diseasesJulien Haroche
Blood|September 5, 2015
mTOR: a new target in Erdheim-Chester disease?Julien Haroche, Zahir Amoura
Hematology. American Society of Hematology. Education Program|December 6, 2015
Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester diseaseJulien Haroche, Oussama Abla
Blood|February 20, 2025
Deciphering Langerhans cell histiocytosisJulien Haroche, Levi-Dan Azoulay
European Journal of Internal Medicine|December 16, 2025
Perisplenic fibrosisTom Abrassart, Olivier Lucidarme, Julien Haroche
Arthritis and Rheumatism|February 24, 2010
The presence of atherosclerotic plaques in patients with Takayasu arteritis: comment on the article by Keenan et alLaurent Arnaud, Julien Haroche, Zahir Amoura
Current Opinion in Rheumatology|November 18, 2011
Erdheim-Chester diseaseJulien Haroche, Laurent Arnaud, Zahir Amoura
The New England Journal of Medicine|April 6, 2018
More on Ofatumumab for TTPFleur Cohen Aubart, Julien Haroche, Zahir Amoura
Antimicrobial Agents and Chemotherapy|July 18, 2002
Tn5406, a new staphylococcal transposon conferring resistance to streptogramin a and related compounds including dalfopristinJulien Haroche, Jeanine Allignet, Névine El Solh
Blood|February 29, 2020
Erdheim-Chester diseaseJulien Haroche, Fleur Cohen-Aubart, Zahir Amoura
Pageof 29

Showing results (1-10 of 284) with videos related to

Sort By:
Pageof 29
Pediatric Blood & Cancer|January 10, 2017
Targeting BRAK, MEK, mTOR, and now AKT in histiocytosis: The ongoing revolution of therapies in orphan diseasesJulien Haroche
Blood|September 5, 2015
mTOR: a new target in Erdheim-Chester disease?Julien Haroche, Zahir Amoura
Hematology. American Society of Hematology. Education Program|December 6, 2015
Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester diseaseJulien Haroche, Oussama Abla
Blood|February 20, 2025
Deciphering Langerhans cell histiocytosisJulien Haroche, Levi-Dan Azoulay
European Journal of Internal Medicine|December 16, 2025
Perisplenic fibrosisTom Abrassart, Olivier Lucidarme, Julien Haroche
Arthritis and Rheumatism|February 24, 2010
The presence of atherosclerotic plaques in patients with Takayasu arteritis: comment on the article by Keenan et alLaurent Arnaud, Julien Haroche, Zahir Amoura
Current Opinion in Rheumatology|November 18, 2011
Erdheim-Chester diseaseJulien Haroche, Laurent Arnaud, Zahir Amoura
The New England Journal of Medicine|April 6, 2018
More on Ofatumumab for TTPFleur Cohen Aubart, Julien Haroche, Zahir Amoura
Antimicrobial Agents and Chemotherapy|July 18, 2002
Tn5406, a new staphylococcal transposon conferring resistance to streptogramin a and related compounds including dalfopristinJulien Haroche, Jeanine Allignet, Névine El Solh
Blood|February 29, 2020
Erdheim-Chester diseaseJulien Haroche, Fleur Cohen-Aubart, Zahir Amoura
Pageof 29